BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for diseases involving the CB1 receptor, today announces a second positive recommendation from the Independent Data Monitoring Committee (“IDMC”) reviewing the safety data of the ongoing Phase 2b study with AEF0217 in adults and older adolescents (16-17 years of age) with Down syndrome. Following this revie